Drugs / Leucogen
Leucogen
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07380646 | Jan 2026 → Jan 2028 expected | breast cancer, neutropenia | Second Affiliated Hospital, Zhejiang University, School of Medicine | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07578064 | Aug 2025 → Sep 2026 overdue | bone marrow disorder, breast cancer | Hongxia Wang | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07418879 | Feb 2026 → Dec 2027 expected | RET fusion positive cancer, non-small cell lung carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07205536 Comparator | Aug 2025 → Dec 2027 expected | bone marrow failure syndrome, neoplasm of thorax | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 3 | NCT05780294 Comparator | Apr 2023 → Dec 2025 overdue | bone marrow failure syndrome, nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leucogen | “the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer” NCT07380646 ↗4“decide whether to intervene with leucogen tablets or other granulocyte-boosting agents” NCT07205536 ↗ “they took Leucogen Tablets (20 mg, three times a day)” NCT07578064 ↗ |
| Known as | Leukogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314921 ↗ |
| Known as | NSC-400257 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314921 ↗ |
| Modality | Small molecule | — CHEMBL5314921 ↗ |
| Route | Oral | “continued orally” NCT05780294 ↗ |